Aligos Therapeutics, Inc.
Nasdaq · Healthcare · Biological Products, (No Diagnostic Substances) · South San Francisco, CA
ALGS chart
What traders are saying about $ALGS
Latest postsAligos Therapeutics, Inc. news
- Weekly Recap: Q3 2026 results and $25 million Amoytop licensing deal
TradingView ·
- Aligos Therapeutics Inc (5WK0.DU) Seasonal Returns Chart - Yahoo Finance
Yahoo! Finance Canada ·
- Form 8K Aligos Therapeutics Inc For: 6 November By Investing.com
Investing.com Canada ·
- Aligos Therapeutics Q3 net loss narrows on lower R&D costs
TradingView ·
- Aligos Therapeutics 3Q 2026: EPS ($2.09) — 10-Q Summary
TradingView ·
- Aligos Therapeutics Reports Recent Business Progress and Third Quarter 2026 Financial Results
Yahoo Finance ·
- Aligos Therapeutics reports positive data on li...
Pluang ·
- Aligos Therapeutics Presents Positive Data at The Liver Meeting® 2026
Yahoo Finance ·
- Aligos Therapeutics Announces Five Abstracts Accepted for Presentation at The Liver Meeting® 2026
Yahoo Finance ·
- Aligos Therapeutics to Present at the Cantor Global Healthcare Conference
Yahoo Finance ·
- Aligos Therapeutics Shares Rise 7.6% Premarket Following Recent Company Updates
investorshub.advfn.com ·
- Aligos Therapeutics Announces First Participant Dosed in the Phase 1 Study of its Potentially Best-in-Class Antisense Oligonucleotide ALG-170675 by its Partner Amoytop in China
Yahoo Finance ·
Aligos Therapeutics, Inc. key financials
| USD | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Revenue | $2.2M | $3.6M | $6.2M | $0 |
| Net income | -$24.2M | -$131.2M | -$87.7M | -$96.0M |
| Diluted EPS | $-2.45 | $-20.94 | $-34.20 | $-2.25 |
| Total assets (year end) | $88.5M | $70.1M | $151.5M | $146.7M |
| Cash and equivalents (year end) | $18.3M | $37.0M | $135.7M | $81.3M |
Calendar-year figures as reported to the SEC in XBRL filings.
Recent SEC filings
About Aligos Therapeutics, Inc.
- Ticker
- ALGS (Nasdaq)
- Industry
- Biological Products, (No Diagnostic Substances)
- Headquarters
- South San Francisco, CA
- Incorporated in
- DE
- Fiscal year end
- December 31
- SEC CIK
- 1799448
Frequently asked questions
What exchange is Aligos Therapeutics, Inc. listed on?
Aligos Therapeutics, Inc. trades on the Nasdaq under the ticker symbol ALGS.
What industry is Aligos Therapeutics, Inc. in?
Aligos Therapeutics, Inc. is classified by the SEC under "Biological Products, (No Diagnostic Substances)", part of the Healthcare sector on StockTweeting.
Where is Aligos Therapeutics, Inc. headquartered?
Aligos Therapeutics, Inc.'s business address on file with the SEC is in South San Francisco, CA.
When does Aligos Therapeutics, Inc.'s fiscal year end?
Aligos Therapeutics, Inc.'s fiscal year ends on December 31.
How much revenue did Aligos Therapeutics, Inc. report?
Aligos Therapeutics, Inc. reported $2.2M in revenue for calendar year 2025, according to its SEC filings.